Dr Reddy's launches generic cholesterol-lowering drug in US

Dr Reddy's Laboratories today launched generic version of Pfizer's Caduet tablets, a cholesterol-lowering drug, in the American market after getting the approval from the US health regulator.

The company has launched Amlodipine Besylate and Atorvastatin Calcium Tablets in the US market following the approval by the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a statement.

The company's product is the generic equivalent of Pfizer Inc's Caduet tablets, it added.

The Hyderabad-based firm's Amlodipine Besylate and Atorvastatin Calcium tablets are available in bottle counts of 30 and 90, the company said.

According to IMS Health sales data, Caduet tablets brand and generics had US sales of around USD 163 million for the most recent twelve months ending in January 2014.

Dr Reddy's Laboratories shares were trading at Rs 2,594 apiece on the BSE in afternoon trade, down 1.60 per cent from its previous close.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Sebi’s latest ban on 260 entities plugs a major loophole for stock manipulation

    Last week, the capital market regulator, Securities and Exchange Board of India (Sebi) banned 260 entities from dealing in the securities market for m

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Taslima Nasreen

Religious conversion as fundamental right

Tricks and treats, coercion, threats, manhandling and extermination are the ...

Purnendu Ghosh

Does speed liberate or enslave humans?

Speed is the reflection of modernity and modernisation. Speed is ...

Shona Adhikari

Why Indian art auctions are here to stay

With Christie’s second India sale just over in Mumbai, we ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture